Proteotype Diagnostics Joins EU's HER-CARE Network, Pioneering Precision Oncology Advancements

Proteotype Diagnostics Enters HER-CARE Doctoral Network

Proteotype Diagnostics Ltd, a groundbreaking diagnostics firm, has recently been selected as an industrial beneficiary in the HER-CARE Marie Skłodowska-Curie Doctoral Network (MSCA-DN). This European research initiative focuses on enhancing outcomes for individuals afflicted with hereditary and early-stage breast cancer. This selection signifies a pivotal moment for Proteotype as it continues to establish itself as a leader in the sphere of precision oncology research, joining a prestigious ensemble of cancer research institutions across Europe.

The HER-CARE consortium boasts esteemed partners including the Karolinska Institutet, University of Cambridge, Institute of Cancer Research (London), Institut Gustave Roussy, Netherlands Cancer Institute, and the Medical University of Vienna. This program aims to unite academic, clinical, and industry partners to cultivate future researchers while fostering innovation in the research and treatment of hereditary and early-onset breast cancer. It emphasizes an interdisciplinary approach, incorporating genomics, proteomics, imaging, and clinical data science to refine early detection methods, elevate risk assessments, and advance treatment protocols.

As part of this collaborative initiative, Proteotype will recruit a doctoral candidate to lead a three-year PhD project dedicated to the development and validation of circulating proteomic biomarkers tailored for early breast cancer detection and predicting therapeutic responses. By investigating how these proteomic signatures can be synthesized with clinical and epidemiological datasets, the project aspires to enhance the reliability of treatment response predictions, particularly for patients undergoing neoadjuvant therapies. The overarching goal is to facilitate more personalized treatment strategies and potentially enable less invasive care pathways over time.

The successful candidate for this PhD position will be employed by Proteotype Diagnostics and enrolled at the Medical University of Vienna. Dr. Yen Tan will serve as the primary academic supervisor, with support from Dr. Klaus Kratochwill. This initiative builds upon Proteotype's proprietary proteomic biomarker platform, designed to analyze amino-acid-resolved protein signatures in blood samples. This technology has demonstrated exceptional efficacy in identifying early-stage (Stage I–II) breast cancer, in addition to accurately predicting and monitoring the efficacy of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i).

This project expands upon Proteotype's ongoing clinical research, including the UK-based INTENTION study, which rigorously assesses the capabilities of its blood-based test to identify patients likely to respond positively to CDK4/6 inhibitor therapy during the adjuvant treatment phase. Despite the revolutionary impact these therapies have had on many patients diagnosed with hormone receptor-positive breast cancer, a notable percentage remain unresponsive, and a validated predictive method for determining treatment suitability is currently lacking.

Dr. Emma Yates, co-founder and Chief Scientific Officer of Proteotype Diagnostics, expressed her enthusiasm about joining the HER-CARE doctoral network, stating, "We are excited to collaborate with world-renowned academic partners such as the Medical University of Vienna. This project marks a critical advancement for our proteomic biomarker platform, aimed at enhancing early cancer detection and facilitating informed, data-driven treatment choices."

Echoing this sentiment, Dr. Yen Tan from the Medical University of Vienna commented, "This collaboration presents a vital opportunity to merge advanced proteomic biomarkers with clinical and epidemiological data. By fusing academic insights with industrial innovation, we can expedite the application of these methodologies into clinically relevant strategies for tailored patient care."

Recruitment for the PhD position is currently underway, with the aspiring candidate anticipated to commence their role in autumn 2026. The HER-CARE initiative is graciously funded by the European Union's Horizon Europe program under the Marie Skłodowska-Curie Actions.

About Proteotype Diagnostics Ltd

Proteotype is a trailblazing diagnostics company dedicated to the crafting of innovative multi-cancer early detection tests and personalized medicine solutions that assess the body's response to tumor development. By harnessing cutting-edge technologies combined with extensive research, Proteotype aspires to transform cancer diagnostics, ultimately leading to better early detection and improved patient outcomes.